Cardiovascular Events in Chronic Obstructive Pulmonary Disease: Squeezing ETHOS Dry for Clinical Evidence at Risk of Type I Error.
作者信息
Calzetta Luigino, Rogliani Paola
机构信息
Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy; and.
Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
出版信息
Am J Respir Crit Care Med. 2025 Mar;211(3):526-527. doi: 10.1164/rccm.202410-1922LE.
Abstract
摘要
相似文献
1
Cardiovascular Events in Chronic Obstructive Pulmonary Disease: Squeezing ETHOS Dry for Clinical Evidence at Risk of Type I Error.慢性阻塞性肺疾病中的心血管事件：为避免I型错误风险而竭力挖掘临床证据。
Am J Respir Crit Care Med. 2025 Mar;211(3):526-527. doi: 10.1164/rccm.202410-1922LE.
2
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).三联疗法对慢性阻塞性肺疾病心血管及严重心肺事件的影响：一项随机、双盲、3期临床试验（ETHOS）分析
Am J Respir Crit Care Med. 2025 Feb;211(2):205-214. doi: 10.1164/rccm.202312-2311OC.
3
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.布地奈德/格隆溴铵/富马酸福莫特罗与糠酸氟替卡松/乌美溴铵/维兰特罗相比在慢性阻塞性肺疾病中降低死亡风险：基于ETHOS和IMPACT的匹配调整间接比较
Curr Med Res Opin. 2023 Oct;39(10):1395-1405. doi: 10.1080/03007995.2023.2247969. Epub 2023 Aug 29.
4
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.布地奈德/格隆溴铵/富马酸福莫特罗二水化合物三联疗法与中重度至极重度慢性阻塞性肺疾病的双重疗法相比的成本效益：ETHOS 研究的英国分析。
Int J Chron Obstruct Pulmon Dis. 2022 Nov 22;17:2987-3000. doi: 10.2147/COPD.S381138. eCollection 2022.
5
Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial.慢性阻塞性肺疾病患者心血管事件的裁定：SUMMIT 试验。
Clin Trials. 2020 Aug;17(4):430-436. doi: 10.1177/1740774520920897. Epub 2020 May 22.
6
β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.β受体阻滞剂治疗中度慢性阻塞性肺疾病合并心血管风险增高患者的临床结局。SUMMIT 的一项观察性亚研究。
Ann Am Thorac Soc. 2018 May;15(5):608-614. doi: 10.1513/AnnalsATS.201708-626OC.
7
Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies.大环内酯类抗生素治疗下呼吸道感染后心血管事件的发生：两项前瞻性队列研究分析。
BMJ. 2013 Mar 20;346:f1235. doi: 10.1136/bmj.f1235.
8
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.ETHOS 研究中布地奈德/格隆溴铵/福莫特罗治疗慢性阻塞性肺疾病降低全因死亡率：一项随机、双盲、多中心、平行分组研究。
Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC.
9
Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.COPD 患者风险、加重累积负担与死亡率之间的关系：来自 ETHOS 研究数据的建模分析。
BMC Med Res Methodol. 2022 May 25;22(1):150. doi: 10.1186/s12874-022-01616-7.
10
PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population.普罗米修斯：在美国慢性阻塞性肺疾病人群中实施单吸入器三联疗法的长期病情加重和死亡率获益情况
J Health Econ Outcomes Res. 2023 Jan 24;10(1):20-27. doi: 10.36469/001c.55635. eCollection 2023.
本文引用的文献
1
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).三联疗法对慢性阻塞性肺疾病心血管及严重心肺事件的影响：一项随机、双盲、3期临床试验（ETHOS）分析
Am J Respir Crit Care Med. 2025 Feb;211(2):205-214. doi: 10.1164/rccm.202312-2311OC.
2
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.布地奈德/格隆溴铵/富马酸福莫特罗与糠酸氟替卡松/乌美溴铵/维兰特罗相比在慢性阻塞性肺疾病中降低死亡风险：基于ETHOS和IMPACT的匹配调整间接比较
Curr Med Res Opin. 2023 Oct;39(10):1395-1405. doi: 10.1080/03007995.2023.2247969. Epub 2023 Aug 29.
3
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS.布地奈德/格隆溴铵/富马酸福莫特罗二水合物在 COPD 加重、肺功能、症状和生活质量方面的获益与血嗜酸性粒细胞范围的相关性：来自 ETHOS 的事后分析数据。
Int J Chron Obstruct Pulmon Dis. 2022 Dec 6;17:3061-3073. doi: 10.2147/COPD.S374670. eCollection 2022.
4
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.在慢性阻塞性肺疾病患者中，先前使用吸入性皮质类固醇与布地奈德/格隆溴铵/富马酸福莫特罗二水化合物对加重、症状、健康相关生活质量和肺功能的获益之间的关系：来自 ETHOS 研究的分析。
Respir Med. 2022 Jun;197:106857. doi: 10.1016/j.rmed.2022.106857. Epub 2022 Apr 22.
5
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial.在 COPD 患者中，布地奈德/格隆溴铵/福莫特罗富马酸酯干粉吸入剂双联治疗改善肺功能：ETHOS 试验的一项亚研究。
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211034329. doi: 10.1177/17534666211034329.
6
Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies.含中剂量吸入性糖皮质激素的固定剂量复方制剂可降低慢性阻塞性肺疾病患者的全因死亡率：对双联和三联疗法的深入分析
Expert Rev Respir Med. 2022 Mar;16(3):357-365. doi: 10.1080/17476348.2021.1951237. Epub 2021 Jul 31.
7
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial.在 ETHOS 试验中，布地奈德/格隆溴铵/富马酸福莫特罗（BGF）对 COPD 患者症状和生活质量的益处。
Respir Med. 2021 Aug-Sep;185:106509. doi: 10.1016/j.rmed.2021.106509. Epub 2021 Jun 18.
8
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.ETHOS 研究中布地奈德/格隆溴铵/福莫特罗治疗慢性阻塞性肺疾病降低全因死亡率：一项随机、双盲、多中心、平行分组研究。
Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC.
9
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.中重度至极重度 COPD 患者两种糖皮质激素剂量三联吸入治疗。
N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24.
10
Is ICS-LAMA an alternative option to treat patients with COPD?吸入性糖皮质激素-长效β2受体激动剂联合制剂（ICS-LAMA）是治疗慢性阻塞性肺疾病（COPD）患者的一种替代选择吗？
Lancet Respir Med. 2018 May;6(5):316-317. doi: 10.1016/S2213-2600(18)30139-5. Epub 2018 Apr 5.
Zotero 插件